Pliant Therapeutics Inc expected to post a loss of 77 cents a share - Earnings Preview

Pliant Therapeutics

03/11/2023 12:14

* Pliant Therapeutics Inc  PLRX.OQ   PLRX.O  is expected
to show a
fall in quarterly revenue when it reports  results 
    * The South San Francisco California-based  company is
expected to
report  a 49.4% decrease in revenue to $750 thousand from $1.48
million a year ago, according to the mean estimate from 10
analysts, based on LSEG data. 
    * ​Refinitiv's mean analyst estimate for Pliant Therapeutics
Inc
is for a loss of 77 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 13 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Pliant
Therapeutics Inc is $48​, above​ its last closing price
of $15.04. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.72       -0.71      -0.70     Beat    1.9
 Mar. 31 2023  -0.65       -0.67      -0.67     Met     -0.2
 Dec. 31 2022  -0.70       -0.70      -0.72     Missed  -2.8​
 Sep. 30 2022  -0.74       -0.74      -0.65     Beat    12.3
 ​​Jun.        -0.82       -0.81      -0.82     Missed  -1
 30 2022                                                
 Mar. 31 2022  -0.73       -0.75      -0.78     Missed  -4​
 Dec. 31 2021  -0.76       -0.76      -0.68     Beat    10.4
 Sep. 30 2021  -0.68       -0.69      -0.75     Missed  -8.7
 This summary was machine generated November 3 at 12:14 GMT.  All
figures in US dollars  unless otherwise stated